L'Oréal announced an increase in its stake in Galderma to 20%, deepening the luxury conglomerate's position in medical aesthetics and dermatology. The move reflects L'Oréal's strategy to integrate prestige skincare with clinical injectables and devices—a convergence play that has defined recent M&A in the space.